An ultimate relevant translational scientific endeavour that contributes to human vulnerability and happiness might be the creation and advancement of medications. Fast drug discovery procedures necessitate using contemporary computational approaches to tackle pharma data's complexities and high complexity. By combining Evolutionary Computing with Hybrid Artificial Neural Networks (EC-HANNs), this research introduces a novel strategy for optimizing and speeding up the drug development process. To handle various drug-target relations, predict the efficacy of compounds, and discover more accurate potential medications, the proposed model employs EC to evolve the computational construction and hyperparameters of HANNs in real-time. This innovation makes the model a flexible framework. Through repeated refinement of EC- HANN designs, the EC Module uses Particle Swarm Optimization (PSO) to choose the best configuration for individual drug discovery tasks. The model's distinctive feature is that it dynamically adjusts the network configuration to match the details of each drug discovery activity by using PSO to optimize the HANN's architecture and hyperparameters. Regarding sequential biological data, the HANN Module employs Convolutional Neural Networks (CNNs) to glean features for pattern recognition over time. By extracting high-level spatial information from genetic data, CNN can better identify prospective medication candidates. When tested on several benchmark datasets, the proposed framework demonstrates superior performance over traditional neural networks across the board regarding prediction accuracy, convergence speed, and model durability. As a powerful tool, this hybrid approach can simplify drug discovery, leading to more efficient drug development.
Read full abstract